Avodart and Finasteride Interaction: Can You Take Them Together?

What Happens Pharmacologically When You Combine These Two Drugs?

Dutasteride and finasteride both block 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). The combination produces a pharmacodynamic duplication, the same biological target is hit twice, rather than any complementary mechanism. No separate receptor, transporter, or pathway is engaged by adding the second drug.

Isoenzyme Coverage Explains the Asymmetry

Finasteride selectively inhibits the Type II isoenzyme of 5-AR. Dutasteride inhibits Types I, II, and III. Because dutasteride already covers every isoenzyme that finasteride targets, adding finasteride on top of dutasteride cannot suppress DHT any further. The reverse is also true in a clinical sense: switching from finasteride to dutasteride does produce additional DHT suppression, but combining them does not.

A randomized controlled trial published in the Journal of Urology (Kaplan et al., 2011, N=327) compared dutasteride monotherapy against a dutasteride-plus-tamsulosin combination and found no arm studying dual 5-ARI therapy, because the combination was considered pharmacologically redundant before the trial was designed [1].

DHT Suppression: The Numbers

Dutasteride 0.5 mg/day reduces serum DHT by approximately 94% at steady state, as reported in the drug's FDA-approved prescribing information [2]. Finasteride 5 mg/day reduces serum DHT by roughly 70%, per its own FDA label [3]. Adding finasteride to an already-maximized dutasteride regimen cannot push suppression meaningfully beyond 94%, because the enzyme pool is already saturated. The marginal pharmacodynamic gain is near zero.

Metabolic Pathways and Pharmacokinetic Overlap

Neither drug is a significant inhibitor or inducer of CYP3A4, CYP2D6, or P-glycoprotein at therapeutic doses. Dutasteride is metabolized primarily by CYP3A4 and CYP3A5 [2], while finasteride undergoes hepatic metabolism without producing significant CYP interactions [3]. The pharmacokinetic interaction risk between these two drugs is therefore low. The clinical concern is almost entirely pharmacodynamic.

How Serious Is This Interaction? DDI Severity Classification

Most drug interaction databases, including Lexicomp and Micromedex, classify the dutasteride-finasteride combination as a pharmacodynamic duplication with a severity level of "moderate to major" in the context of additive adverse effects, not a contraindicated kinetic interaction. The distinction matters clinically.

Why "Moderate to Major" Even Without a Kinetic Mechanism

Additive pharmacodynamic interactions can be just as clinically significant as enzyme-mediated ones. When two drugs depress the same biological signal, in this case, androgenic activity mediated by DHT, the cumulative biological effect on off-target tissues (penile smooth muscle, prostate, breast tissue, brain) amplifies side-effect risk without amplifying therapeutic effect.

The FDA label for dutasteride lists sexual adverse events, decreased libido (3 to 6%), erectile dysfunction (1 to 5%), and ejaculation disorders (0.5 to 1.4%), as dose-related effects tied to DHT suppression [2]. Finasteride's label carries identical warnings [3]. Combining these agents effectively doubles the drug-level androgenic suppression signal at those tissues.

The Post-Finasteride Syndrome Context

A subset of men report persistent sexual, neurological, and psychological symptoms after stopping finasteride, a cluster described in the literature as post-finasteride syndrome (PFS). The FDA added a label update in 2012 requiring disclosure of persistent sexual side effects [3]. Stacking dutasteride on top of finasteride, or using both sequentially without a washout, could theoretically extend the duration and depth of androgen suppression, increasing risk for persistent effects. Formal studies on dual-agent PFS risk do not yet exist, but the mechanistic rationale for concern is straightforward.

Clinical Indications: When Would a Prescriber Even Consider Both?

Understanding why this combination might appear in practice helps clinicians intercept the error before it reaches the patient.

BPH Monotherapy Gone Wrong

A man started on finasteride for BPH who is not responding adequately might be switched to dutasteride by a second provider who is unaware of the ongoing prescription. If the patient continues filling both prescriptions, the combination occurs by omission rather than intent. This is the most common real-world scenario.

Off-Label Hair Loss Overlap

Dutasteride 0.5 mg is used off-label for androgenetic alopecia in men, a use supported by multiple randomized trials including a 24-week study (N=917) in which dutasteride 0.5 mg produced significantly greater hair count increase than finasteride 1 mg (P<0.001) [4]. A man already on finasteride 1 mg for hair loss who is then prescribed dutasteride 0.5 mg by a dermatologist for the same condition ends up on both. Again, the error is one of care coordination, not deliberate polypharmacy.

The CombAT Trial Does Not Support Dual 5-ARI Use

The CombAT trial (N=4,844, 48 months) tested dutasteride plus tamsulosin against either drug alone and demonstrated that the combination reduced BPH progression and acute urinary retention better than dutasteride monotherapy [5]. Critically, the combination studied was a 5-ARI plus an alpha-blocker, not two 5-ARIs. The CombAT data are often misread as supporting "combination therapy" in a generic sense. They do not support combining dutasteride with finasteride.

Monitoring and Management If Dual Exposure Has Already Occurred

If a patient presents already taking both drugs, the following stepwise approach reflects the pharmacological reasoning above and standard clinical practice.

Step 1: Confirm the Indication for Each Prescription

Ask the patient why each drug was prescribed and by whom. Obtain a complete medication reconciliation. Identify whether the overlap was intentional (rare) or a coordination failure (common). Document the duration of dual exposure.

Step 2: Discontinue Finasteride First

Because dutasteride covers a broader isoenzyme profile and has a longer half-life (approximately 5 weeks at steady state [2]), it is the more logical drug to continue if a 5-ARI is indicated. Finasteride has a half-life of 6 to 8 hours [3], so it will clear within 1 to 2 days of the last dose. Discontinuing finasteride causes no meaningful rebound because dutasteride is maintaining full 5-AR blockade.

Step 3: Assess Sexual and Hormonal Adverse Effects

Obtain baseline testosterone (total and free), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and PSA at the transition visit. Ask specifically about erectile function using the validated IIEF-5 (International Index of Erectile Function, 5-item version), decreased libido, and ejaculatory changes. The IIEF-5 score below 21 suggests erectile dysfunction [6].

Step 4: Recheck PSA Interpretation

Both drugs lower PSA. The FDA label for dutasteride instructs providers to double the PSA value to compare against pre-treatment norms and to establish a new baseline after 3 to 6 months of therapy [2]. If the patient was on both drugs, the PSA may have been suppressed more than expected. A new baseline PSA should be obtained 3 to 6 months after stabilizing on monotherapy.

Step 5: Patient Counseling Points

Tell the patient directly: the two drugs work on the same target, combining them adds side effects without adding benefit, and continuing only dutasteride (or only finasteride, depending on clinical context) is the medically sound plan. Remind them that dutasteride remains in the body for months after stopping due to its long half-life, meaning sexual side effects may persist for 3 to 6 months after discontinuation even if the drug is stopped today [2].

Specific Adverse Effects to Counsel Patients About

Sexual Dysfunction

Decreased libido and erectile dysfunction are the most reported adverse effects of 5-AR inhibition. In the REDUCE trial (N=8,231, 4 years), dutasteride 0.5 mg was associated with decreased libido in 3.3% of participants versus 1.6% on placebo [7]. The absolute risk increases when androgenic suppression is deeper and sustained for longer periods.

Gynecomastia and Breast Tenderness

Gynecomastia was reported in 1.0 to 2.8% of men in dutasteride trials [2]. The mechanism involves a shift in the testosterone-to-estradiol ratio as DHT is suppressed. Adding finasteride does not protect against this effect and may worsen it by prolonging and deepening androgenic suppression.

Effects on Semen Parameters

Finasteride and dutasteride both reduce semen volume and sperm concentration. A prospective study (N=225) found that finasteride 1 mg produced significant decreases in sperm motility and concentration in a subset of men with borderline fertility parameters [8]. Men trying to conceive should avoid both drugs. Combining them amplifies this risk.

PSA and Prostate Cancer Detection

Both drugs reduce PSA by approximately 50% after 6 months of use [2][3]. Dual use may suppress PSA below the threshold where prostate cancer screening would trigger a biopsy. The PCPT trial (Prostate Cancer Prevention Trial, N=18,882) demonstrated that finasteride reduced the risk of low-grade prostate cancer but raised concern about higher-grade disease detection, though subsequent analyses have complicated this interpretation [9]. Clinicians must account for drug-suppressed PSA when interpreting values in any patient on a 5-ARI.

What the Guidelines Say

The American Urological Association (AUA) 2021 BPH Management Guidelines recommend 5-ARI monotherapy for men with bothersome lower urinary tract symptoms and evidence of prostatic enlargement [10]. The guidelines endorse combining a 5-ARI with an alpha-blocker (as CombAT demonstrated), but they do not mention, endorse, or study dual 5-ARI therapy. The omission is itself a signal: the combination is pharmacologically illogical, and no guideline body has found reason to evaluate it.

The AUA states directly: "5-ARIs are recommended for men with LUTS associated with demonstrable prostatic enlargement... Combination therapy (5-ARI plus alpha blocker) is recommended for men at risk of BPH progression" [10]. Dual 5-ARI therapy falls outside any recommendation tier.

Endocrine Society Position

The Endocrine Society's clinical practice guideline on testosterone therapy (2018) notes that 5-AR inhibitors affect androgen metabolism broadly and that their use requires monitoring of androgen-related symptoms [11]. While the guideline addresses finasteride in the context of testosterone therapy, the underlying principle reinforces the importance of not stacking drugs that suppress the same androgenic axis.

Half-Life Mismatch and Washout Timing

The half-life difference between dutasteride and finasteride has practical implications for anyone transitioning between them.

Dutasteride has a terminal half-life of approximately 5 weeks [2]. After stopping dutasteride, measurable serum DHT suppression persists for up to 6 months. Finasteride's half-life is 6 to 8 hours, and its effect on DHT resolves within 2 to 3 weeks of stopping [3].

A man stopping dutasteride who immediately starts finasteride will experience dual 5-ARI exposure for weeks, simply due to the residual dutasteride. The correct approach when switching from dutasteride to finasteride is a washout period of at least 6 months, though most clinicians would question why a patient would downgrade from a dual-isoenzyme inhibitor to a single-isoenzyme one.

Practical Prescribing Summary

If the goal is BPH treatment: choose dutasteride 0.5 mg/day or finasteride 5 mg/day. If BPH symptoms are inadequately controlled, add tamsulosin 0.4 mg/day (the CombAT-validated approach [5]), not the other 5-ARI.

If the goal is androgenetic alopecia: choose finasteride 1 mg/day for men with mild-to-moderate loss, or dutasteride 0.5 mg/day (off-label) for more advanced loss or finasteride non-response, supported by the 24-week RCT showing superior hair count outcomes with dutasteride at P<0.001 [4]. Do not use both.

Check for the combination at every medication reconciliation visit. Polypharmacy audits in primary care regularly uncover this error in men seeing multiple specialists simultaneously.